Sentences with phrase «alk inhibitor»

As a result, Shaw's team has begun another clinical trial with a more potent ALK inhibitor — LDK378, a drug made by Novartis — that might take over when Xalkori becomes less effective.

Commenting on the trial, Dr Alice Shaw, director of thoracic oncology at the Massachusetts General Hospital Cancer Centre in Boston, US, said: «This is the first randomised study to examine how a second generation ALK inhibitor compares to standard second line chemotherapy in ALK positive patients who failed the standard first line therapy, which currently is crizotinib.»

He continued: «This was the first phase III study to assess whether the second generation ALK inhibitor ceritinib was superior to chemotherapy upon progression on crizotinib therapy in NSCLC.»

The latter trial addresses one of the most fundamental questions in the field, which is what should be the first ALK inhibitor that patients receive.»

This will establish sequential crizotinib followed by a second generation ALK inhibitor as the standard treatment for patients with metastatic ALK positive lung cancer.»

Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

The FDA has approved several ALK inhibitors for treating non-small cell lung cancer.

She concluded: «We are now waiting on the results of trials testing the second generation ALK inhibitors ceritinib (versus chemotherapy) and alectinib (versus crizotinib) in the first line setting.

Partnering with the U.S. Food and Drug Administration allowed Doebele and colleagues to access clinical trial data describing initial tumor response, PFS and OS for 305 patients with stage IIIb or IV non-small cell lung cancer on trials of ALK inhibitors and 355 similar patients on trials of immunotherapies directed at PD - 1.

Phase 2 Trial of Brigatinib after Treatment with Second - Generation ALK Inhibitors in Refractory ALK Rearranged NSCLC

Several prospective studies show a brain metastasis prevalence of 40 % to 70 % in patients previously treated with ALK inhibitors.

Not exact matches

Now the next - generation ALK - inhibitor, alectinib, shows PFS of nearly 25 months.

«Patients with non-small cell lung cancer (NSCLC) should receive front line therapy with the anaplastic lymphoma kinase (ALK) inhibitor crizotinib,» said lead author Professor Giorgio Scagliotti, head of the Department of Oncology, University of Turin, Italy.

Kinases are also druggable targets, as seen by the success of kinase - inhibitors in earning FDA approval (including, for example, crizotinib against ALK - fusion and erlotinib against EGFR).

Thus, alectinib has been developed and approved for use as an ALK kinase inhibitor.

BETHESDA, MD. — June 28, 2016 — The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised evidence - based guideline, «Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors.»

A and B, two ALK + ALCL cell lines, Karpas 299 and SU - DHL1, were treated with the selective PI3K inhibitor, LY294002, at a concentration of 0, 5, 10, or 20 μg / μL.